Venoarteriovenous ECMO in Concomitant Acute Respiratory Distress Syndrome and Cardiomyopathy Associated with COVID-19 Infection
Author(s) -
Zachary Bergman,
Saranya Prathibha,
Brent D. Bauman,
Demetris Yannopoulos,
Melissa E. Brunsvold
Publication year - 2021
Publication title -
case reports in critical care
Language(s) - English
Resource type - Journals
eISSN - 2090-6439
pISSN - 2090-6420
DOI - 10.1155/2021/8848013
Subject(s) - ards , cardiogenic shock , extracorporeal membrane oxygenation , medicine , concomitant , mechanical ventilation , cardiomyopathy , ejection fraction , cardiology , acute respiratory distress , cardiac surgery , intensive care medicine , shock (circulatory) , anesthesia , lung , heart failure , myocardial infarction
In the most severe cases, novel coronavirus (SARS-CoV-2) infection leads to Acute Respiratory Distress Syndrome which may be refractory to standard medical interventions including mechanical ventilation. There are growing reports of the use of venovenous (VV) extracorporeal membrane oxygenation (ECMO) in these cases. A subset of critically ill COVID-19 patients develops cardiomyopathy as well, manifested by cardiogenic shock with reduced ejection fraction, dysrhythmias, and subsequent increase in mortality. One strategy for managing ARDS with an element of cardiogenic shock is venoarteriovenous (VAV) ECMO. Less than 1% of the cases in the worldwide ELSO COVID-19 database employed any form of hybrid cannulation. To date, there has only been one reported case of patient salvage with arterial or partial arterial support. We present a case that demonstrates the potential role of VAV ECMO in the case of concomitant severe ARDS with cardiomyopathy in the setting of COVID-19 infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom